StemCell Therapy

What happened

Cellect Biotechnology (NASDAQ: APOP) stock is up nearly 30% at 12:06 p.m. EST after the company announced that it treated the first patient in the biotech's phase 1/2 trial, dubbed ApoGraft01, testing its stem cell technology ApoGraft in patients with blood cancer.

Treating the first patient shouldn't have come as much of a surprise to investors. In November, the company said the Israeli Ministry of Health had given its approval to begin the trial. Perhaps investors are just really happy that the trial is finally starting. Also keep in mind that Cellect Biotechnology has a fairly low market cap, so the relative increase in valuation wasn't that much.

Image source: Getty Images.

Cellect Biotechnology's ApoGraft attempts to better select stem cells to help prevent graft-versus-host disease (GvHD), which occurs in 25% to 50% of recipients of allogeneic stem cell transplantation. GvHD happens when the donated stem cells produce immune cells that start mistakenly attacking the patients' normal cells because they see it as foreign. GvHD leads to 15% of the deaths that occur after allogeneic stem cell transplantation.

Continue Reading Below

ADVERTISEMENT

ApoGraft01 will enroll 12 patients, so it shouldn't take too long for Cellect Biotechnology to fully enroll the trial. Before data from that trial reads out, investors will get results from a trial testing ApoGraft in healthy volunteers by the end of the first quarter.

While Cellect Biotechnology is progressing, investors should proceed with caution given the biotech's precarious capital situation. At the end of September, Cellect Biotechnology had just $9.4 million in cash and cash equivalents on the books. The company may be able to raise additional capital, but most biotechs raise capital through secondary offerings, diluting shareholders' equity in the process.

10 stocks we like better than Cellect Biotechnology When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now and Cellect Biotechnology wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Visit link:
Why Cellect Biotechnology Ltd Shares Skyrocketed Higher Today - Fox Business

WASHINGTON--(BUSINESS WIRE)--Today the Biotechnology Innovation Organization (BIO) announcedregistrationandhousingare now openfor the2017 World Congress on Industrial Biotechnology. The conference will be held July 23-26, 2017 at the Palais des congrs de Montral in Montral, Canada.

Now in its 14th year, BIO continues to bring new and exciting features to its annual World Congress on Industrial Biotechnology, stated Brent Erickson, Executive Vice President, Industrial and Environmental at BIO.Two new tracks-Flavors, Fragrances and Food Ingredients and Agricultural Crop Technologies and Biomass Supply-have been added to this years programming to represent the extended value chain of industrial biotechnology. Additionally, BIO brought The World Congress back to Montral so attendees from all over the world can gather and meet in one international location to make those important industry connections.

BIOs World Congress on Industrial Biotechnology is the worlds largest industrial biotechnology conference that brings together from across the globe business leaders, investors, academics and policymakers in the biofuels, biobased products, renewable chemicals, synthetic biology, food ingredients and biomass sectors. Industrial and environmental biotechnology is at the forefront of the biobased economy, generating good-paying jobs and making cleaner products and processes.

In 2016, the BIOWorld Congress on Industrial Biotechnologydrew around 907 industry leaders from 529 companies, 32 countries and 31 states, as well as the District of Columbia and hosted a record1,961 partnering meetings.

All programs at the World Congress on Industrial Biotechnology are open to attendance by members of the media. Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials. For more information and to register, please visithttps://www.bio.org/events/conferences/world-congress-media

For more information on the conference please visithttp://www.bio.org/worldcongress. For assistance, please contactworldcongress@bio.org.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces theBIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.BIOtechNOWis BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter.Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO CEO & Investor Conference February 13-14, 2017 New York, NY

BIO Asia International Conference March 14-15, 2017 Tokyo, Japan

BIO-Europe Spring Conference March 20-22, 2017 Barcelona, Spain

See the article here:
Registration Now Open for the 14th Annual BIO World Congress on ... - Business Wire (press release)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:00 a.m. EST on Wednesday, February 15, at the LEERINK Partners 6th Annual Global Healthcare Conference. The conference will be held at the Lotte New York Palace Hotel in New York City.

A live webcast of the presentation will be available on the Companys website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidatesPB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Go here to see the original:
Puma Biotechnology to Present at LEERINK Partners Global ... - Business Wire (press release)

After the United Kingdom voted to leave the European Union, dubbed Brexit by the press, many have called into question whether the UK would ratify the Unitary Patent System. The Unitary Patent System will create a Unitary Patent and a Unitary Patent Court (UPC) system to enforce patents across many European states. Brexit was especially troublesome for those in the biotechnology field because the UPC was planning to hold many of its human necessities patent cases in its London based court. Following Brexit, there have been several new developments with regard to the UPC, but these events have not eased the uncertainty felt in the biotechnology field.

One such development is that the UK government, which is one of the 13 member states that necessarily must adopt the UPC agreement for it to take force, recently announced that it would in fact ratify the Agreement. This is good news for those interested in the time and cost savings associated with filing and enforcing a Unitary Patent. A single Unitary Patent will streamline the expansive filing process normally associated with many biotechnology and pharmaceutical patent applications. Additionally, litigation at a single system of courts will consolidate patent enforcement thereby streamlining proceedings, reducing costs, and facilitating the ability for global patentees to take consistent positions when defending or asserting their patents. Accordingly, the UKs recent announcement and the opening of the UPC, which may take place as soon as December 2017, may benefit small to mid-size companies with limited resources.

However, news of the UKs announcement to ratify the UPC Agreement is tempered by the UK Prime Minster Theresa Mays speech calling for an end to the EUs and the European Court of Justices (ECJ) jurisdiction over the UK. Theresa Mays comments are in conflict with the UKs announcement to ratify the agreement because under the Unitary Patent System, ECJ decisions will be binding on the UPC, and in turn, the ECJ will retain jurisdiction over the UK through these patent courts. Although this contradiction may be resolved through negotiations between the UK and the EU, it is feared that such deal making may only further delay the institution of the Unitary Patent System.

After many set-backs in bringing a Unitary Patent System to Europe and the latest launch date slated for the end of 2017, the biotechnology industry may have to continue to hold its breath for the Unitary Patent and the determination of the location of the UPCs biotechnology arm.

For more information on the Unitary Patent, please see our previous article at https://www.knobbe.com/news/2016/09/continental-patents-la-carte-or-prix-fixe-biotechnology-considerations-unitary-patent.

Continue reading here:
Biotechnology Considerations for the Unitary Patent System in Light of Brexit and Other Current Developments - Lexology (registration)

Insider Selling: Puma Biotechnology Inc (PBYI) Insider Sells ... Sports Perspectives Puma Biotechnology Inc (NYSE:PBYI) insider Robert Charnas sold 3008 shares of the firm's stock in a transaction that occurred on Wednesday, February 1st. Puma Biotechnology Inc Risk Points versus Health Care - CMLvizCML News The Puma Biotechnology Inc (PBYI) Insider Sells $95744.64 in StockDailyQuint Robert Charnas Sells 3008 Shares of Puma Biotechnology Inc (PBYI) StockCommunity Financial News all 8 news articles »

View original post here:
Insider Selling: Puma Biotechnology Inc (PBYI) Insider Sells ... - Sports Perspectives

Jon Entine, Executive Director, Genetic Literacy Project,oversaw the assignments and the editing of this series

INTRODUCTION:

Genetically engineered crops and animals (GMOs) have been a controversial public issue since the first products were introduced in the 1990s. They have posed unique challenges for governments to regulate. Although most working scientists in the field hold the opinion that genetic engineering, for the most part, is part of a continuum of the human manipulation of our food supply thats gone on for thousands of years, critics contend differently.

Many crop biotechnology skeptics frame their concerns in quasi-religious terms, as a violation of nature or fears that the increased use of GE foods will lead to a corporate takeover of our seed and food systems, and the adoption of an ecologically destructive industrialized agriculture system. GMOs have become a symbol of the battle over what our global, regional and local food systems should look like going forward.

The clout of the food movement that vocally rejects many aspects of conventional farming has exponentially increased since then, promoted by mainstream journalists, scientists and non-profit groups from Michael Pollan to Consumers Union to the Environmental Working Group. Organic leaders and lobbyists, such as Gary Hirshberg, founder of Stonyfield Organics and Just Label It, openly demonize conventional food and farming in defiance of their commitments agreed to in the 1990s that organic food would not be promoted at the expense of conventional agriculture. Attempts to reign in the unchecked influence of the conventional food critics have repeatedly failed; over much of the past decade, theyve had a sympathetic ear in Washington. Partly in response to the prevailing winds, the USDA has evolved increasingly byzantine regulatory structures when it comes to new GE products.

The Genetic Literacy Project 10-part series Beyond the Science II (Beyond the Science I can be viewed here) commences with this introductory article. Leading scientists, journalists and social scientists explore the ramifications of genetic engineering and so-called new breeding technologies (NBTs), specifically gene-editing technologies such as CRISPR. We will post two articles each week, on Tuesday and Wednesday, over the next 5 weeks.

Regulation is at the heart of this ongoing debate. Many scientists and entrepreneurs have come to view the two key agencies regulating GE in the United States the Food and Drug Administration and Department of Agriculture as places where innovation goes to die. Thats an exaggeration, but not without some truth; regulations are inherently political, and the winds have been blowing against technological breakthroughs in agriculture for much of the last decade. On average, it takes upwards of $125 million and 7-10 years for the Agriculture Department to approve a trait, exhausting almost half of a new products 20-year patent protection. No wonder the agricultural sector is consolidating, and most new products are innovated by larger corporations.

The regulatory climate may be changing, perhaps radically, in the United States and possibly in the United Kingdom, as the result of recent elections.

Many of the old rules and regulations regulating GE crops were set up in the 1980s and early 1990s. They are arguably creaky, overly-restrictive and do not account for dramatic increases in our understanding of how genetic engineering works and the now clear consensus on their safety.

Now with NBTs, which are largely unregulated since the techniques were not foreseen 30 years ago when regulations were first formulated, agricultural genetic research is at an inflection point: Will governments make the same mistake that they did previously and regulate innovation almost out of existence, or will they incorporate reasonable risk-risk and risk-benefit calculations in evaluating which technological advances should proceed with limited regulations?

Decisions on these issues will shape not only food and farming in Europe, North America and the industrialized nations, but the food insecure developing world, which looks to the West for regulatory guidance.

Gene Editing and Animals

The second article in our series, by University of California animal geneticist Alison Van Eenennaam, addresses the challenges of regulating genetically engineered animals. She focuses on dehorned cows, which have been developed without gene editing over many years with, at times, less than optimal results. Should gene editing be evaluated on a case-by-case basis triggered by the novelty of the traits, or should the entire process be heavily regulated the general approach favored by the European Union in regulating more conventional genetic engineering?

Pesticide Debate: How Should Agricultural Chemicals Be Regulated to Encourage Sustainability?

Dave Walton, an Iowa farmer, discusses the brouhaha that has erupted in recent years over the use of glyphosate, the active ingredient in the weed killer originally developed under patent by Monsanto. Many GMO critics are now expressing concerns over pesticide use in conventional agriculture, using glyphosate as a proxy for attacking the technology. Are their concerns appropriate? Walton, who grows both GE and non-GE crops and is director of the Iowa Soybean Association, has used glyphosate on his farm since the introduction of herbicide resistant crops in 1996. He uses on average a soda-sized cup of glyphosate per acre, and the use of the herbicide has allowed him to switch from more toxic chemicals. Most strikingly he discusses the sustainability impact if a glyphosate ban is imposed, as many activists are calling for.

Plant pathologist Steve Savage challenges us to think in a more nuanced way about a popular belief that organic farming is ecologically superior to conventional agriculture. The Agricultural Department has been a fractious mess in recent years in its efforts to oversee and encourage new breeding technologies. When the Clinton administration oversaw the founding of the National Organics Standards Board in 1995, USDA officials extracted the commitment from organic industry that the alternative farming system would not be promoted at the expense of conventional agriculture. After all, study after study, then and now, has established that organic farming offers no safety nor clear ecological benefits.

Let me be clear about one thing, said former Secretary of Agriculture Dan Glickman in December 2000. The organic label is not a statement about food safety, nor is organic a value judgment about nutrition or quality.

But thats not whats happened.

Regulations and the NGO Problem in Africa and Asia

While GE crops were pioneered in the United States and embraced in other western coun- tries outside of Europe, there has been resistance in regions of the world where these innovations could arguably bring the most impact: Africa and poorer sections of Asia. Ma- haletchumy Arujanan, executive director of Malaysian Biotechnology Information Centre and editor-in-chief of The Petri Dish, the first science newspaper in Malaysia, takes on the emerging Asian food security crisis posed by a parallel rise in population and living (and food consumption) standards. She reviews the successes and failures in various countries, and the effective campaigns by anti-GMO NGOs, mostly European funded, to block further biotech innovation.

Margaret Karembu, director of International Service for the Acquisition of Agribiotech Applications, Africa regional office (ISSSA) AfriCenter based in Nairobi, has found a similar pattern of mostly European-funded NGOs attempting to sabotage research and spread misinformation about the basic science of crop biotechnology. Africa is the ultimate organic experiment, and farmers have failed miserably using family agro-ecology techniques for decades. Cracks are beginning to form in the anti-GMO wall erected across the continent and there are hopes that young people will be attracted to farming, lured by the introduction of GE crops and other innovations.

Public Opinion and GMOs

Brandon McFadden, assistant professor in the Food and Resource Economics Department, University of Florida, addresses the complex views of consumers regarding innovation and GE foods. The public has a widely distorted perception of what genetic engineering entails, which helps explain why consumers remain so skeptical about technological innovation in farming.

Julie Kelly, a contributing writer to numerous publications including the Wall Street Journal, National Review and the GLP, takes on Hollywood in her analysis of the celebrity embrace of the anti-GMO movement. Who are the movers and shakers manipulating public opinion in favor of the organic movement and against conventional agriculture? Is the celebrity-backed science misinformation campaign working?

Future of GM Research and How the Public Debate May Evolve

Paul Vincelli, extension professor and Provosts Distinguished Service Professor at the University of Kentucky, has been perturbed about the attack on independent university researchers for working with the biotechnology industry over the years. By law, land grant university scientists are required to work with all stakeholders, particularly corporations who are developing the products used by farmers, including organic farmers. No, scientists who partner with corporations in research and product development are not shills. He rejects the knee jerk belief, advanced by many activist critics of GE crops, that corporate funding necessarily corruptsscience and should be banned.

Finally, risk expert David Ropeik has an optimistic take on the future. He believes 2016 may have been a turning point in the debate over GE foods. Technology rejectionists, from Greenpeace to labeling activists, are sounding increasingly shrill and less scientific. Gene editing, he believes, could undercut claims that GE foods are unsafe because they are unnatural. He is convinced, perhaps optimistically, that GE opponents will soon be viewed as science denialists.

We will see.

Anti-GMO critics cite opinion polls and the votes of anti-GMO legislators in Europe and elsewhere as proof that genetic engineering should be curtailed and more heavily regulated. Thats a rickety platform if one believes in science, however; science is not a popularity contest.

The Genetic Literacy Project is a 501(c)(3) non profit dedicated to helping the public, journalists, policy makers and scientists better communicate the advances and ethical and technological challenges ushered in by the biotechnology and genetics revolution, addressing both human genetics and food and farming. We are one of two websites overseen by the Science Literacy Project; our sister site, the Epigenetics Literacy Project, addresses the challenges surrounding emerging data-rich technologies.Jon Entineis the founder of the Science Literacy Project.

Follow this link:
Will Biotechnology Regulations Squelch Food and Farming Innovation? - Genetic Literacy Project

Forbes

Beyond Bricks And Mortar: Reimagining Infrastructure Investment To Spur Biotechnology Innovation Forbes Biotechnology (including not only biopharmaceuticals, but also bioengineered food products, biofuels and biodefense mechanisms) is primed for an infusion of infrastructure investment. By supplementing existing tools with robotics, advanced computing ...

More:
Beyond Bricks And Mortar: Reimagining Infrastructure Investment To Spur Biotechnology Innovation - Forbes

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Animal Biotechnology - Technologies, Markets and Companies" to their offering.

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals. There is discussion of in vitro meat production by culture.

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine.

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Biotechnology products are approved by the Center for Veterinary Medicine of the FDA. Regulatory issues relevant to animal biotechnology are described.

Approximately 124 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 108 collaborations in this area are shown.

Share of biotechnology-based products and services in 2015 is analyzed and the market is projected to 2025.

The text is supplemented with 35 tables and 5 figures.Selected 260 references from the literature are appended.

Key Topics Covered:

Executive Summary

1. Introduction to Animal Biotechnology

2. Application of Biotechnology in Animals

3. A Biotechnology Perspective of Animals Diseases

4. Molecular Diagnostics in Animals

5. Biotechnology-based Veterinary Medicine

6. Research in Animal Biotechnology

7. Animal Biotechnology Markets

8. Regulatory issues

9. Companies Involved in Animal Biotechnology

10. References

For more information about this report visit http://www.researchandmarkets.com/research/b9fmth/animal

View source version on businesswire.com: http://www.businesswire.com/news/home/20170203005322/en/

Original post:
Animal Biotechnology Technologies, Markets and Companies 2017 - Research and Markets - Yahoo Finance

Puma Biotechnology Inc (NYSE:PBYI) insider Robert Charnas sold 3,008 shares of Puma Biotechnology stock in a transaction dated Wednesday, February 1st. The stock was sold at an average price of $31.83, for a total transaction of $95,744.64. Following the completion of the sale, the insider now directly owns 28,461 shares in the company, valued at approximately $905,913.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Puma Biotechnology Inc (NYSE:PBYI) traded up 0.75% during trading on Thursday, reaching $33.45. 527,529 shares of the company traded hands. The companys 50-day moving average price is $33.44 and its 200-day moving average price is $45.94. Puma Biotechnology Inc has a 52 week low of $19.74 and a 52 week high of $73.27. The companys market capitalization is $1.23 billion.

PBYI has been the topic of several research reports. J P Morgan Chase & Co set a $89.00 price objective on shares of Puma Biotechnology and gave the stock a buy rating in a research report on Monday, November 14th. Citigroup Inc. set a $88.00 price objective on shares of Puma Biotechnology and gave the stock a buy rating in a research report on Monday, November 14th. Stifel Nicolaus reaffirmed a buy rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research report on Thursday, November 10th. Zacks Investment Research lowered shares of Puma Biotechnology from a buy rating to a hold rating in a research report on Tuesday, January 10th. Finally, Cowen and Company reaffirmed a market perform rating on shares of Puma Biotechnology in a research report on Tuesday, November 15th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the companys stock. Puma Biotechnology currently has a consensus rating of Hold and a consensus price target of $68.56.

A number of institutional investors have recently bought and sold shares of PBYI. Redmile Group LLC bought a new position in Puma Biotechnology during the third quarter valued at about $44,406,000. Janus Capital Management LLC boosted its position in Puma Biotechnology by 30.6% in the second quarter. Janus Capital Management LLC now owns 2,540,331 shares of the biopharmaceutical companys stock valued at $75,675,000 after buying an additional 594,821 shares in the last quarter. EverPoint Asset Management LLC bought a new position in Puma Biotechnology during the second quarter valued at about $13,406,000. BlackRock Fund Advisors boosted its position in Puma Biotechnology by 160.7% in the second quarter. BlackRock Fund Advisors now owns 602,071 shares of the biopharmaceutical companys stock valued at $17,936,000 after buying an additional 371,151 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Puma Biotechnology by 22.3% in the second quarter. Point72 Asset Management L.P. now owns 1,415,800 shares of the biopharmaceutical companys stock valued at $42,177,000 after buying an additional 258,100 shares in the last quarter. Institutional investors and hedge funds own 80.98% of the companys stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

Read this article:
The Puma Biotechnology Inc (PBYI) Insider Sells $95744.64 in Stock - DailyQuint

Artizan is a newly created biotechnology company headquartered in Durham, North Carolina, with labs in New Haven, Connecticut, that was founded to address diseases involving the human intestinal microbiota.

Irish based life sciences company Malin said on Monday that it has acquired a 32 per cent shareholding of US biotechnology company Artizan Biosciences.

Dublin-based Malin, which has invested more than 300 million in life sciences companies since it was established in early 2015, invested in Artizan via a founding equity round alongside Hatteras Venture Partners, a venture capital firm with which Malin has a strategic partnership.

Artizan is a newly created biotechnology company headquartered in Durham, North Carolina, with labs in New Haven, Connecticut, that was founded to address diseases involving the human intestinal microbiota. It was spun out of Yale University and established as a standalone business in 2016 and its founders include Prof. Richard Flavell, Noah Palm, PhD, and Marcel de Zoete, PhD, from Yale University. Artizan, which aims to be a leader in the microbiota-driven inflammatory diseases space, has developed a capability of distinguishing certain pathogenic bacteria from the remainder of the intestinal microbiota. The ability to target these specific bacteria could lead to treatment options for any number of digestive disorders as well as other diseases including obesity, autoimmune disease and a wide variety of skin, lung and central nervous system (CNS) diseases.

Artizans proposed approach is disruptive to current treatment and would offer new and novel therapeutic options for patients suffering from a broad array of inflammatory disorders, Adrian Howd, chief investment officer of Malin, said.

Last month Malin acquired a 33 per cent shareholding of Wren Therapeutics, a newly created biopharmaceutical company based in Cambridge, UK. It was set up by a number of former Elan executives in 2015.

Read more from the original source:
Malin stakes 32% take in US biotechnology company Artizan - Irish Times

Commentary | Feb. 3, 2017

Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil

Should Christians face unethical uses of biotechnology with despair and resignation or with hope and determination?

Ive spent the last decade writing and speaking about the remarkable and terrifying world of biotechnology from a Catholic perspective. Many times Ive felt like Frodo Baggins at the gates of Mordor, looking upon Mt. Doom with despair and dread.

Ive never felt this more acutely than in the past few months. A series of recent headlines have renewed my sense of hopelessness in the face of the never-ending assault on the dignity of human life by modern biotechnology.

The gloom began to settle when it was revealed that a Swedish scientist is editing the DNA of healthy human embryos.Fredrik Lanner,a developmental biologist, is using a new gene-editing technique called CRISPR to disable some genes in healthy human embryos to see how those genes affect development. He and his team are intentionally modifyingotherwise healthy IVFembryos so they cannot develop properly.

Anin-depth story byNPRreveals that while the reporter was observing thegeneticmanipulation of five donated IVF embryos, one didnt survive the thawing process and one perished after being injected with the experimental gene-editing tool. Of the three who survived, one continued to divide, but not for long.All of the embryos were to be destroyedbefore they are 15 days old,as the law in Sweden dictates. Lanner insists that his research is critical to understanding human development, which, in turn, will shed light on infertility and disease.

Lanners work makes many ethicists and scientists extremely nervous. Jennifer Doudna, the co-inventor of CRISPR, along with other heavy-hitting scientists,havecalled for a voluntary moratorium on any editing of human embryosfor fear that it will lead to the creation of genetically modified children. Marcy Darnovsky, of the left-leaning Center for Genetics and Society, explains why she and her group havebeen so vocal in their opposition to the modification of human embryos. She told NPR: The production of genetically modified human embryos is actually quite dangerous. ... When youre editing the genes of human embryos, that means youre changing the genes of every cell in the bodies of every offspring, every future generation of that human being. So these are permanent and probably irreversible changes that we just dont know what they would mean.

Then came the revelation that a U.S. doctor traveled to Mexico to create the first baby intentionally engineered to have three genetic parents. This technique, misnamed mitochondrial replacement or MR, seeks to eliminate the transmission of genetic disease through the mitochondria.Mitochondria are small but abundant organellesoutside the nucleusinthe cytoplasmof our cells that make energy. They have their own DNA called mtDNA. We inherit our mtDNA solely from our mothers. A woman who carries a deleterious mutation in her mtDNA cannot help but pass that on to her offspring.

There are various MR techniques that replace the mitochondria of a woman with mitochondrial disease with the mitochondria of a donor femalein the IVF process.Essentially, MR creates a genetically alteredembryo with the genetic material from three people, one man and two women.

MR had only undergone limited study in primates before getting approval in the United Kingdom for use in fertility clinics to make babies. Little is known about the complexcommunication between the DNA in the nucleus and the DNA in the mitochondria,and so there is little data on the effects ofa mismatch between the nuclear DNA and mtDNA.

Alsoin all MR, its the nucleus thats being moved from cell to cell, not the mitochondria which is why mitochondrial replacement is such a misnomer.This makes MR acousin to cloning, which also transplants the nucleus of one cell into anotherto make a new organism. MR brings with it many of the same risks.Scientists are concerned about the health of the resulting children.

In anopen letterto the U.K. Parliament, Dr. Paul Knoepfler, a vocal American stem-cell researcher, warned: Even if, hypothetically, this technology might help avoid some people from having mitochondrial disorders (and thats a big if), the bottom line is that there is an equal or arguably greater chance that it will tragically produce very ill or deceased babies.

MRis also a germ-line genetic modification, which means that any girl born with this technique will pass her genetic modification on to her children.

A recent review in Nature reveals that MR leaves a tiny percentage of mutant mitochondria behind, and sometimes the mutant mitochondria rapidly divide and overtake the healthy mitochondria. Shoukhrat Mitalipov, head of the Center for Embryonic Cell and Gene Therapy at the Oregon Health and Science University, reported a 15% failure rate where mitochondrial defects returned. Mitalipov told NPR, That original, maternal mitochondrial DNA took over, and it was pretty drastic. There was less than 1% of the original maternal mitochondrial DNA present after replacement with donor DNA and before fertilization, and yet it took over the whole cell later. University of California San Francisco professor Patrick OFarrell suggests that mutant mitochondria can resurge at any time in a developing three-parent child or even resurface in future generations.

For all these reasons, MR is not yet approved by the FDA in the United States,and may never be.So, when a Jordanian woman with mitochondrial disease wanted to have a child using MR, John Zhang, from the New Hope Fertility Center in New York City, had to perform the procedure in Mexico. He created five embryos,and, according toNewScientist.com,only one developed normally. That child is now 9 months old.

Zhang went to Mexico because, he said, there are no rules, and yet he insists he did the safe and ethical thingin the absence of any medical or ethical oversight. In an ironic twist, the couple is Muslim and so chose the MR technique that wouldnt destroy existing embryos.But it was clear that only male embryos would be transferred for gestation, because boys cant pass on the genetic modification. What happened to the other four embryos, however? Were they destroyed,discarded or frozen? If they were females, would they have been destroyed anyway to make sure they couldnt pass on any ill effects?

Darnovskycalledthis rogue experimentationand added, No researcher or doctor has the right to flout agreed-upon rules and make up their own. This is an irresponsible and unethical act.

Knoepflerrespondedto the news by remindingus that this is a living human experiment that is going to unfold over years and decades. It is also worth noting that this child is a genetically modified human being as a result of this technique.

Of course, these are happenings to despair of not only because of the sheer disregard for the sanctity of individual human lives, but because of the breakneck speed at which scientists are kicking ethical lines farther and farther down the road like a tin can. All the while, they insist that its for the good of humanity. I wonder: How can wetreatindividual members of the human species so callously and then, at the same time, say its for the good of the whole human race?

I fear there is no line we wont cross;no ethical boundary wewonttear down in the name of science.

On a daily basis, Im surrounded by science and scientists. Often, their response to this madness is that its going to happen anyway, and theres no way to stop it, which implies we must go along to get along all in the name of progress.

If I am Frodo, then they and the rest of society are Saruman giving in to the despair and making a deal with Sauron.In the film version of The Lord of the Rings, Saruman says to Gandalf: Against the power of Mordor there can be no victory. We must join with him, Gandalf. We must join with Sauron. It would be wise, my friend.

Gandalf replies, Tell me, friend, when did Saruman the Wise abandon reason for madness?

Indeed. When did science abandon reason for madness, ethics for recklessness?

So what shall we do? If wesuccumb to despair, we become like Saruman.

We always have prayer. Its time toadd human embryonic research and germ-line human genetic engineering to our list of life issues that we pray about.It doesnt matter whether we understand the finer points of the science or not.Praying for an end to abortion andassisted suicide is nolongerenough.

In addition to prayer, there are other things we can do. The first is to vote pro-life at every level of government, from city council to state assemblymen. Being pro-life isnt just about abortion, however. Its about protecting the sanctity of life from the beginning to the end. Pro-life legislators, even if they cannot overturn Roe v. Wade, can effect local and state laws and steer funding away from unethical research.

Secondly, we must fight for conscience rights for medical professionals. I envision a not-so-far-off world wheredoctorsare forced into making genetically engineered embryos and bringing these children to term simply because parents claim its their reproductive right to have the children of their design. Without conscience rights, unethical experimentation on the next generation will be rampant and unchecked.

We must, however, always have hope. Whenstaring downthe juggernaut that is modern biotechnology, I always remember Frodo Baggins.When he was faced with the seemingly impossible task of taking the One Ring to Mordor, instead of shying away because it was too hard, he said: I will take the Ring, though I do not know the way.

Rebecca Tayloris a

clinical laboratory specialist in molecular biology.

She writes about bioethics on her blog,Mary Meets Dolly.

Excerpt from:
Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil - National Catholic Register

President Trump pressed Big Pharma executives to increase U.S. production and lower drug prices.

As biotechnology stocks have been showing momentum following a meeting between President Trump and pharmaceutical executives Tuesday, our two long investments to watch are in that sector. There are also several shorts among our charts to watch to play the potential downside in this near-term, toppy-looking stock market.

Gene-therapy company bluebird bio Inc. BLUE, -2.10% has a strong-looking chart. The stock recently broke out of a wedge pattern, in which its price range had narrowed for two months in essentially a sideways direction. The stock continued the upmove on Tuesday when it popped $5.90, or over 8%, to $74.50, and followed through for another $1.10 on Wednesday to $75.60. The stock is now positioned to challenge its recent high at $79.70 from early December. A break through there could lead to a move into the mid-$80s, followed by a next target in the mid-$90s. With short interest of 9.2 its average volume, the price advance could be further fueled by short covering.

Cara Therapeutics Inc. CARA, -0.90% a cannabis-based biotech, has been steadily climbing since the start of the year. On Wednesday, the stock popped $1.17, or 7.6%, to $16.49 on 4.7 million shares, which is huge volume for this stock, the biggest since mid-November. The stock got as high as $17.20 intraday before pulling back into the close. It is a bit extended near the top of its channel and could pull back and consolidate before its next move, but momentum could carry it a bit further toward $18.

On the short side, Carters Inc. CRI, +0.26% continues lower since its July 2016 top above $112. On Wednesday, shares in the childrens wear retailer were down another $1.05, or 1.3%, to $82.70, on 690,100 shares traded. The stock appears headed toward the bottom of its declining channel in the $73-$74 range.

Signet Jewelers Ltd. SIG, -0.67% is also continuing lower. The stock rallied from the bottom of its declining price channel to the top in the last quarter of 2016, but has since broken down. Shares fell another 66 cents to $77.01 on 1.5 million shares traded on Wednesday. Watch for a test of the late-September low in the $72-$73 range. A takeout of that could drop the stock near its channel bottom in the low- to mid-$60s.

See Harrys video chart analysis on these and other stocks.

The writer has no holdings in any securities mention in this article.

Harry Boxer is the founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis and live chart presentations.

Follow this link:
Opinion: Harry Boxer: Watch these two biotechnology stocks - MarketWatch

More Volatility Ahead for Biotechnology Sector Wall Street Journal (blog) After underperforming the S&P 500 over the past six months, the biotechnology sector is poised for more volatility ahead. The group drew plenty of attention on the campaign trail as both and Democratic candidate criticized the high prices for drugs ...

Link:
More Volatility Ahead for Biotechnology Sector - Wall Street Journal (blog)

Intrexon Corporation (XON) ended last trading session with a change of 5.25 percent. It trades at an average volume of 1.33M shares versus 1.7M shares recorded at the end of last trading session. The share price of $22.04 is at a distance of 8.09 percent from its 52-week low and down -45.23 percent versus its peak. The company has a market cap of $2.61B and currently has 118.35M shares outstanding. The share price is currently -5.82 percent versus its SMA20, -16.17 percent versus its SMA50, and -17.92 percent versus its SMA200. The stock has a weekly performance of 2.04 percent and is -9.3 percent year-to-date as of the recent close.

Jan. 26, 2017 Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (XON) committed to enabling the study of life-threatening human diseases, has been awarded a subcontract to create genetically engineered miniswine models of sickle cell disease as part of a national resource that could lead to new treatments for the disorder.

The subcontract is with Leidos Biomedical Research, Inc., prime contractor for the Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute, part of the National Institutes of Health (NIH). Work under the subcontract will support the NIHs National Center for Advancing Translational Sciences (NCATS) in creating genetically engineered miniswine models of sickle cell disease. Exemplar Genetics will develop several versions of genetically engineered miniswine models of sickle cell disease that more accurately replicate the human pathology as compared to traditional research models.

Keryx Biopharmaceuticals, Inc. (KERX) recently recorded -0.55 percent change and currently at $5.45 is 75.24 percent away from its 52-week low and down -30.13 percent versus its peak. It has a past 5-day performance of 13.54 percent and trades at an average volume of 1.61M shares. The stock has a 1-month performance of -12.38 percent and is -7 percent year-to-date as of the recent close. There were about 106.55M shares outstanding which made its market cap $580.7M. The share price is currently -1.7 percent versus its SMA20, -5.27 percent versus its SMA50, and -1.49 percent versus its SMA200.

Nov. 18, 2016 Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, announced case study data, which showed that Auryxia (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. These data were presented in a poster presentation at the American Society of Nephrologys 2016 Kidney Week taking place in Chicago.

The rest is here:
Top Biotechnology Stock Picking: Intrexon Corporation (XON), Keryx Biopharmaceuticals, Inc. (KERX) - The Independent Republic

Achillion Pharmaceuticals, Inc. (ACHN) ended last trading session with a change of 2.61 percent. It trades at an average volume of 2.22M shares versus 1.78M shares recorded at the end of last trading session. The share price of $4.32 is at a distance of 14.29 percent from its 52-week low and down -57.06 percent versus its peak. The company has a market cap of $575.38M and currently has 133.19M shares outstanding. The share price is currently 2.99 percent versus its SMA20, 3.06 percent versus its SMA50, and -38.89 percent versus its SMA200. The stock has a weekly performance of 5.62 percent and is 4.6 percent year-to-date as of the recent close.

On Dec. 28, 2016 Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), related to enrollment in the OMEGA-1 Phase 2b global, clinical trial of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335 in patients with treatment-naive chronic hepatitis C virus infection (HCV) without cirrhosis.

We are delighted to have reached this milestone following Janssens recent initiation of the OMEGA-1 global clinical trial evaluating JNJ-4178, a once-daily combination of AL-335, simeprevir, and the Achillion-discovered NS5A inhibitor, odalasvir, and we look forward to JNJ-4178s continued clinical advancement, commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion.

Stemline Therapeutics, Inc. (STML) recently recorded 16.96 percent change and currently at $6.55 is 68.81 percent away from its 52-week low and down -55.14 percent versus its peak. It has a past 5-day performance of -35.78 percent and trades at an average volume of 285.02K shares. The stock has a 1-month performance of -44.96 percent and is -38.79 percent year-to-date as of the recent close. There were about 20.21M shares outstanding which made its market cap $132.38M. The share price is currently -41.5 percent versus its SMA20, -44.82 percent versus its SMA50, and -29.73 percent versus its SMA200.

Feb. 02, 2017 Stemline Therapeutics, Inc. (STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, provides an update on its ongoing pivotal Phase 2 trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN), using Stemlines experimental compound, SL-401. BPDCN at present has no approved treatment.

On January 18, the Company received a report that a patient death had occurred. The patient had developed capillary leak syndrome (CLS), a known, sometimes fatal, and well-documented side effect of SL-401. The cause of the patients death has not yet been determined. The safety profile for SL-401 includes CLS, and there have been previous deaths reported in patients with CLS in this trial, which have been disclosed in public presentations. That CLS is an expected complication of the administration of SL-401 has also been identified in filings with the Securities and Exchange Commission (SEC) and U.S. Food and Drug Administration (FDA), as well as in the studys informed consent forms and other information provided to investigators.

See the article here:
2 Sizzling Hot Biotechnology Stocks: Achillion Pharmaceuticals, Inc. (ACHN), Stemline Therapeutics, Inc. (STML) - The Independent Republic

Celldex Therapeutics, Inc. (CLDX) ended last trading session with a change of 2.08 percent. It trades at an average volume of 2.28M shares versus 1.33M shares recorded at the end of last trading session. The share price of $3.43 is at a distance of 20.35 percent from its 52-week low and down -60.8 percent versus its peak. The company has a market cap of $340.19M and currently has 99.18M shares outstanding. The share price is currently -2.15 percent versus its SMA20, -7.49 percent versus its SMA50, and -13.68 percent versus its SMA200. The stock has a weekly performance of 1.48 percent and is -3.11 percent year-to-date as of the recent close.

On Dec. 14, 2016 Celldex Therapeutics, Inc. (CLDX) announced the appointment of Gerald McMahon, Ph.D., to the Companys Board of Directors. Dr. McMahon was previously the President and Chief Executive Officer of Kolltan Pharmaceuticals. In addition, the Company announced that Richard van den Broek has resigned from the Board due to increasing responsibilities in other endeavors.

Dr. McMahon brings an exceptional background in science and drug development, particularly in the oncology space, to the Celldex Board, said Larry Ellberger, Chairman of the Board of Directors at Celldex Therapeutics. We believe he will be a valuable addition as we advance a robust pipeline, which now also includes drug candidates targeting receptor tyrosine kinases, an area of expertise for Jerry. I would also like to recognize Rich for his contributions to Celldex. We wish him all the best in his future endeavors.

Eleven Biotherapeutics, Inc. (EBIO) recently recorded 4.61 percent change and currently at $2.27 is 804.38 percent away from its 52-week low and down -61.98 percent versus its peak. It has a past 5-day performance of 4.13 percent and trades at an average volume of 1.15M shares. The stock has a 1-month performance of -1.73 percent and is 18.85 percent year-to-date as of the recent close. There were about 23.17M shares outstanding which made its market cap $52.6M. The share price is currently 5.56 percent versus its SMA20, 4.83 percent versus its SMA50, and -9.19 percent versus its SMA200.

On November 14, 2016 Eleven Biotherapeutics, Inc. (EBIO) reported financial results for the third quarter ended September 30, 2016, and recent business highlights.

This is an exciting period for Eleven. We completed the Roche licensing deal, including $30 million in upfront and milestone payments received to date. We also completed the acquisition of Viventia Bio Inc. which allowed us to become a late-stage oncology company. Perhaps most excitingly, we are making significant progress in moving forward what we believe could be therapeutics that materially improve patients lives. We anticipate complete enrollment in the first half of next year for our Phase 3 clinical trial of Vicinium as a potential treatment for high-grade non-muscle invasive bladder cancer, and expect topline data in the first half of 2018, said Stephen Hurly, President and Chief Executive Officer of Eleven Biotherapeutics. We also plan to initiate our Phase 2 trial in late-stage squamous cell carcinoma of the head and neck with Proxinium in combination with a checkpoint inhibitor in the first half of 2017. Also in 2017, we plan on submitting an IND with the FDA for our lead product in our systemic pipeline based on our proprietary payload deBouganin. With the combined expertise of Eleven and the Viventia team, I am very excited about the opportunities we have ahead.

Go here to read the rest:
Two Biotechnology Names Are Hot: Celldex Therapeutics, Inc. (CLDX), Eleven Biotherapeutics, Inc. (EBIO) - The Independent Republic

Considering a Masters in Biotechnology Program or reviewing options for Masters Degrees in Biotechnology? A Masters in Biotechnology can openupexciting

Biotechnology is a challenging field that can involve a number of facets of both science and business or law. Many biotechnology master's degree programs focus on aspects of biology, cell biology, chemistry, or biological or chemical engineering. In general, biotechnology degrees involve research whether they are at a Masters or PhD level.

Scientific understanding is rapidly evolving, particularly in areas of cellular and molecular systems. Biotechnology master's students can therefore enjoy rich study opportunities particularly in fields such as genetic engineering, the Human Genome project, the production of new medicinal products, and research into the relationship between genetic malfunction and the origin of disease. These are just a few of the many areas that biotechnology students have the opportunity to explore today.

Another focus of biotechnology masters programs may be to equip students with the combination of science and business knowledge they need to help produce products and move them toward production. Today's complex business environment and government regulations require many steps and people with the ability to both understand and help produce new scientific technologies as well as get them approved and be able to market them.

Master degrees in biotechnology might prepare students to pursue careers in a variety of industries. While many students go on to further research or academic positions, there may also be some demand for biotechnologists outside of academia, both in the government and private sectors. Biotechnologists might pursue careers in anything from research to applied science and manufacturing. Those with specializations in business aspects of biotechnology may be qualified to pursue management positions within organizations attempting to produce and market new biotechnology.

More:
Masters in Biotechnology Programs and Degrees in Biotechnology

Biotechnology has proven to be an important tool for better sustainability and food security. It helps farmers grow more food while improving the environment. For example, biotechnology reduces the use of costly inputs and improves weed management, allowing farmers to reduce tillage for better soil, water and air quality. Today, roughly 90 percent of corn, cotton and soybeans grown in the U.S. have been improved through biotechnology, and farmers are choosing biotech traits when growing other crops such as alfalfa, sugarbeets and canola.

Despite rapid adoption by farmers and a strong scientific consensus that biotechnology does not pose health and environmental risks, regulatory burdens are slowing research and innovation of new biotech traits and are starting to reduce U.S. farmers international competitive advantage. In addition, activist groups routinely threaten the availability of new traits by blocking science-based regulatory decisions, filing lawsuits and advocating for labeling mandates.

GM crops require less water and fewer chemical applications than conventional crops, and they are better able to survive drought, weeds, and insects.

U.S. agriculture will maintain its competitive advantage in world markets only if we continue to support innovations in technology and grasp opportunities for future biotech products.

To improve regulation of biotechnology, Farm Bureau supports:

Farm Bureau encourages efforts to educate farmers to be good stewards of biotech crops to preserve accessand marketability.

Farm Bureau believes agricultural products grown using approved biotechnology should not be subject to mandatory labeling. We supportexisting FDA labeling policies and opposestate policies on biotech labeling, identification, use and availability.

On July 29, 2016 the president signed S. 764, the National Bioengineered Food Disclosure Standard, into law. While not perfect, S. 764 was a compromise that Farm Bureau endorsed. The law creates a uniform standard for the disclosure of ingredients derived from bioengineering and allows food companies to provide that information through an on-package statement, symbol or electronic disclosure. It also created a strong federal preemption provision to protect interstate commerce and prevent state-by-state labeling laws and was effective on the date of enactment. USDA has two years to develop the disclosure standards and Farm Bureau will be an active participant in the rulemaking process.

Farm Bureau supports active involvement and leadership by the U.S. government in the development of international standards for biotechnology, including harmonization of regulatory standards, testing and LLP policies.

This resource can help set the record straight on GMOs, to correct misinformation and show why biotechnology is so important to agriculture.

Benefits of Biotech Toolkit (PDF)

Here is the original post:
Biotechnology - fb.org

3 Biotech is a quarterly, peer-reviewed open access journal published under the brand SpringerOpen.

Continuous Article Publishing (CAP)

3 Biotech will be moving to the Continuous Article Publishing (CAP) in 2016, in which newly accepted papers will be published online with volume and article numbers, shortly after receipt of authors proofs. This change will alleviate the significant backlog of accepted articles that are currently available online as "published ahead of time," but are awaiting formal publication with a volume, issue number and page numbers. To achieve a smooth transition to the CAP model, all papers that have been accepted after June 2015 have been held back and will be published with volume and article numbers from January 2016 onwards. We wish to apologize for this short delay in article processing during this important transition phase, which is designed to speed up the process from acceptance of articles to final publication without the need for articles to be placed in a "published ahead of time" waiting line. In addition, a formal rapid publication from 2016 will ensure that all articles in 3 Biotech are immediately available in indexing services for researchers.

3 Biotech publishes the results of the latest research related to the study and application of biotechnology to:

- Medicine and Biomedical Sciences - Agriculture - The Environment

The focus on these three technology sectors recognizes that complete Biotechnology applications often require a combination of techniques. 3 Biotech not only presents the latest developments in biotechnology but also addresses the problems and benefits of integrating a variety of techniques for a particular application. 3 Biotech will appeal to scientists and engineers in both academia and industry focused on the safe and efficient application of Biotechnology to Medicine, Agriculture and the Environment.

Articles from a huge variety of biotechnology applications are welcome including:

- Cancer and stem cell research - Genetic engineering and cloning - Bioremediation and biodegradation - Bioinformatics and system biology - Biomarkers and biosensors - Biodiversity and biodiscovery - Biorobotics and biotoxins - Analytical biotechnology and the human genome

3 Biotech accepts original and review articles as well as short research reports, protocols and methods, notes to the editor, letters to the editor and book reviews for publication. Up to date topical review articles will also be considered. All the manuscripts are peer-reviewed for scientific quality and acceptance.

NEW:

3Biotech hasrecently receivedits first Impact Factor and is nowcovered by a range of A&I services, including:

- Science Citation Index Expanded - Journal Citation Reports/Science Edition - Biological Abstracts - BIOSIS Previews

Best Paper Award: 3 Biotech is supported by King Abdulaziz City for Science and Technology (KACST) in Saudi Arabia. Every year KACST awards the best paper with the KACST Medal and $5,000. The editors of 3 Biotech have elected the best paper among those published in 2011-2012 and 2012-2013.

- The 2011-2012 winning paper is:

Nanocrystalline hydroxyapatite and zinc-doped hydroxyapatite as carrier material for controlled delivery of ciprofloxacin

Authors: G. Devanand Venkatasubbu and colleagues at Anna University, India.

- The 2012-2013winning paper is: Stress influenced increase in phenolic content and radical scavenging capacity of Rhodotorula glutinis CCY 20-2-26 Authors: Raj Kumar Salar and colleagues at Chaudhary Devi Lal University, India.

Related subjects Agriculture - Biomaterials - Biotechnology - Cancer Research - Cell Biology - Systems Biology and Bioinformatics

Journal Citation Reports, Thomson Reuters

Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed, PubMedCentral, EMBASE, Google Scholar, CAB International, AGRICOLA, Biological Abstracts, BIOSIS, CAB Abstracts, DOAJ, Global Health, OCLC, Summon by ProQuest

See original here:
3 Biotech - a SpringerOpen journal

Session & Tracks

Track 1:Molecular Biotechnology

Molecular biotechnology is the use of laboratory techniques to study and modify nucleic acids and proteins for applications in areas such as human and animal health, agriculture, and the environment.Molecular biotechnologyresults from the convergence of many areas of research, such as molecular biology, microbiology,biochemistry, immunology, genetics, and cell biology. It is an exciting field fueled by the ability to transfer genetic information between organisms with the goal of understanding important biological processes or creating a useful product.

Related Conferences

11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA; GlobalBiotechnology Congress2016, May 11th-14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA;BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil;Bio Pharm America 20158th Annual International Partnering Conference, September 15-17, 2015, Boston, MA, USA.

Track 2:Environmental Biotechnology

The biotechnology is applied and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation. It is "the development, use and regulation of biological systems for remediation of contaminated environment and forenvironment-friendly processes(green manufacturing technologies and sustainable development). Environmental biotechnology can simply be described as "the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to producerenewable energy, food and nutrients in a synergistic integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process".

Related Conferences

11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA; GlobalBiotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands

Track 3:Animal Biotechnology

It improves the food we eat - meat, milk and eggs. Biotechnology can improve an animals impact on the environment. Animalbiotechnologyis the use of science and engineering to modify living organisms. The goal is to make products, to improve animals and to developmicroorganismsfor specific agricultural uses. It enhances the ability to detect, treat and prevent diseases, include creating transgenic animals (animals with one or more genes introduced by human intervention), using gene knock out technology to make animals with a specific inactivated gene and producing nearly identical animals by somatic cell nuclear transfer (or cloning).

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 4:Medical Biotechnology and Biomedical Engineering

Medicine is by means of biotechnology techniques so much in diagnosing and treating dissimilar diseases. It also gives opportunity for the population to defend themselves from hazardous diseases. The pasture of biotechnology, genetic engineering, has introduced techniques like gene therapy, recombinant DNA technologyand polymerase chain retort which employ genes and DNA molecules to make adiagnosis diseasesand put in new and strong genes in the body which put back the injured cells. There are some applications of biotechnology which are live their part in the turf of medicine and giving good results.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & Biotech Patent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 5:Agricultural Biotechnology

Biotechnology is being used to address problems in all areas of agricultural production and processing. This includesplant breedingto raise and stabilize yields; to improve resistance to pests, diseases and abiotic stresses such as drought and cold; and to enhance the nutritional content of foods. Modern agricultural biotechnology improves crops in more targeted ways. The best known technique is genetic modification, but the term agricultural biotechnology (or green biotechnology) also covers such techniques asMarker Assisted Breeding, which increases the effectiveness of conventional breeding.

Related Conferences

3rd GlobalFood Safety Conference, September 01-03, 2016, Atlanta USA; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 12thBiotechnology Congress, Nov 14-15, 2016, San Francisco, USA;Biologically Active Compoundsin Food, October 15-16 2015 Lodz, Poland; World Conference onInnovative Animal Nutrition and Feeding, October 15-17, 2015 Budapest, Hungary; 18th International Conference onFood Science and Biotechnology, November 28 - 29, 2016, Istanbul, Turkey; 18th International Conference on Agricultural Science, Biotechnology,Food and Animal Science, January 7 - 8, 2016, Singapore; International IndonesiaSeafood and Meat, 1517 October 2016, Jakarta, Indonesia.

Track 6:Industrial Biotechnology and Pharmaceutical Biotechnology

Industrial biotechnology is the application of biotechnology for industrial purposes, includingindustrial fermentation. The practice of using cells such as micro-organisms, or components of cells like enzymes, to generate industrially useful products in sectors such as chemicals, food and feed, detergents, paper and pulp, textiles andbiofuels. Industrial Biotechnology offers a premier forum bridging basic research and R&D with later-stage commercialization for sustainable bio based industrial and environmental applications.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA; GlobalBiotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 8:Microbial and Biochemical Technology

Microorganisms have been exploited for their specific biochemical and physiological properties from the earliest times for baking, brewing, and food preservation and more recently for producingantibiotics, solvents, amino acids, feed supplements, and chemical feedstuffs. Over time, there has been continuous selection by scientists of special strains ofmicroorganisms, based on their efficiency to perform a desired function. Progress, however, has been slow, often difficult to explain, and hard to repeat. Recent developments inmolecular biologyand genetic engineering could provide novel solutions to long-standing problems. Over the past decade, scientists have developed the techniques to move a gene from one organism to another, based on discoveries of how cells store, duplicate, and transfer genetic information.

Related conferences

3rdGlobal Food Safety Conference, September 01-03, 2016, Atlanta USA; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 12thBiotechnology Congress, Nov 14-15, 2016, San Francisco, USA;Biologically Active Compoundsin Food, October 15-16 2015 Lodz, Poland; World Conference onInnovative Animal Nutrition and Feeding, October 15-17, 2015 Budapest, Hungary; 18th International Conference onFood Science and Biotechnology, November 28 - 29, 2016, Istanbul, Turkey; 18th International Conference on Agricultural Science, Biotechnology,Food and Animal Science, January 7 - 8, 2016, Singapore; International IndonesiaSeafood and Meat, 1517 October 2016, Jakarta, Indonesia.

Track 9:Food Processing and Technology

Food processing is a process by which non-palatable and easily perishable raw materials are converted to edible and potable foods and beverages, which have a longer shelf life. Biotechnology helps in improving the edibility, texture, and storage of the food; in preventing the attack of the food, mainly dairy, by the virus likebacteriophage producing antimicrobial effect to destroy the unwanted microorganisms in food that cause toxicity to prevent the formation and degradation of other toxins andanti-nutritionalelements present naturally in food.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress 2016, May 11th-14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA;BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil;Bio Pharm America 20158th Annual International Partnering Conference, September 15-17, 2015, Boston, MA, USA.

Track 10:Genetic Engineering and Molecular Biology

One kind of biotechnology is gene technology, sometimes called 'genetic engineering' or'genetic modification', where the genetic material of living things is deliberately altered to enhance or remove a particular trait and allow the organism to perform new functions. Genes within a species can be modified, or genes can be moved from one species to another. Genetic engineering has applications inmedicine, research, agriculture and can be used on a wide range of plants, animals and microorganisms. It resulted in a series of medical products. The first two commercially prepared products from recombinant DNA technology were insulin andhuman growth hormone, both of which were cultured in the E. coli bacteria.

The field of molecular biology overlaps with biology and chemistry and in particular, genetics and biochemistry. A key area of molecular biology concerns understanding how various cellular systems interact in terms of the way DNA, RNA and protein synthesis function.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-http://world.biotechnologycongress.com/08, 2015 Berlin, Germany, DEU.

Track 11:Tissue Science and Engineering

Tissue engineering is emerging as a significant potential alternative or complementary solution, whereby tissue and organ failure is addressed by implanting natural, synthetic, orsemisynthetic tissueand organ mimics that are fully functional from the start or that grow into the required functionality. Initial efforts have focused on skin equivalents for treating burns, but an increasing number of tissue types are now being engineered, as well as biomaterials and scaffolds used as delivery systems. A variety of approaches are used to coax differentiated or undifferentiated cells, such as stem cells, into the desired cell type. Notable results includetissue-engineeredbone, blood vessels, liver, muscle, and even nerve conduits. As a result of the medical and market potential, there is significant academic and corporate interest in this technology.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 12:Nano Biotechnology

Nano biotechnology, bio nanotechnology, and Nano biology are terms that refer to the intersection of nanotechnology and biology. Bio nanotechnology and Nano biotechnology serve as blanket terms for various related technologies. The most important objectives that are frequently found inNano biologyinvolve applying Nano tools to relevantmedical/biologicalproblems and refining these applications. Developing new tools, such as peptide Nano sheets, for medical and biological purposes is another primary objective in nanotechnology.

Related Conferences

8thWorldMedicalNanotechnologyCongress& Expo during June 9-11, Dallas, USA; 6thGlobal Experts Meeting and Expo onNanomaterialsand Nanotechnology, April 21-23, 2016 ,Dubai, UAE; 12thNanotechnologyProductsExpo, Nov 10-12, 2016 at Melbourne, Australia; 5thInternationalConference onNanotechand Expo, November 16-18, 2015 at San Antonio, USA; 11thInternational Conference and Expo onNano scienceandMolecular Nanotechnology, September 26-28 2016, London, UK; 18thInternational Conference onNanotechnologyand Biotechnology, February 4 - 5, 2016 in Melbourne, Australia; 16thInternational Conference onNanotechnology, August 22-25, 2016 in Sendai, Japan; International Conference onNano scienceand Nanotechnology, 7-11 Feb 2016 in Canberra, Australia; 18thInternational Conference onNano scienceand Nanotechnology, February 15 - 16, 2016 in Istanbul, Turkey; InternationalNanotechnologyConference& Expo, April 4-6, 2016 in Baltimore, USA.

Track 13:Bioinformatics and Biosensors

Bioinformatics is the application of computer technology to the management of biological information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied to gene-based drug discovery and development. The science of Bioinformatics, which is the melding of molecular biology with computer science, is essential to the use of genomic information in understanding human diseases and in the identification of newmolecular targetsfor drug discovery. This interesting field of science has many applications and research areas where it can be applied. It plays an essential role in today's plant science. As the amount of data grows exponentially, there is a parallel growth in the demand for tools and methods indata management, visualization, integration, analysis, modeling, and prediction.

Related conferences

11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 12thBiotechnology Congress, Nov 14-15, 2016, San Francisco, USA;BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBio based Chemicals: Commercialization & Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnology and Bio economy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnology World Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess Engineering and Technology, 20th to 22nd January 2016,Kolkata, India; GlobalBiotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA

Track 14:Biotechnology investments and Biotech grants

Every new business needs some startup capital, for research, product development and production, permits and licensing and other overhead costs, in addition to what is needed to pay your staff, if you have any. Biotechnology products arise from successfulbiotechcompanies. These companies are built by talented individuals in possession of a scientific breakthrough that is translated into a product or service idea, which is ultimately brought into commercialization. At the heart of this effort is the biotech entrepreneur, who forms the company with a vision they believe will benefit the lives and health of countless individuals. Entrepreneurs start biotechnology companies for various reasons, but creatingrevolutionary productsand tools that impact the lives of potentially millions of people is one of the fundamental reasons why all entrepreneurs start biotechnology companies.

10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok; 11thEuroBiotechnologyCongress, November 7-9, 2016 Alicante, Spain; 11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 13thBiotechnologyCongress, November 28-30, 2016 San Francisco, USA; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, UAE;BioInternational Convention, June 6-9, 2016 | San Francisco, CA;BiotechJapan, May 11-13, 2016, Tokyo, Japan;NANO BIOEXPO 2016, Jan. 27 - 29, 2016, Tokyo, Japan;ArabLabExpo2016, March 20-23, Dubai; 14thInternational exhibition for laboratory technology,chemical analysis, biotechnology and diagnostics, 12-14 Apr 2016, Moscow, Russia

Read this article:
Biotechnology Conferences | USA Biotech events ...